Dyne Therapeutics Company Leadership
| DYN Stock | USD 12.26 0.14 1.13% |
Dyne Therapeutics employs about 191 people. The company is managed by 17 executives with a total tenure of roughly 446 years, averaging almost 26.0 years of service per executive, having 11.24 employees per reported executive. Analysis of Dyne Therapeutics' management performance can provide insight into the firm performance.
Dyne |
Dyne Therapeutics Management Team Effectiveness
The company has Return on Asset of (0.502) % which means that on every $100 spent on assets, it lost $0.502. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.8803) %, meaning that it generated no profit with money invested by stockholders. Dyne Therapeutics' management efficiency ratios could be used to measure how well Dyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Dyne Therapeutics Workforce Comparison
Dyne Therapeutics is rated # 5 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,741. Dyne Therapeutics holds roughly 191 in number of employees claiming about 7% of equities under Health Care industry.
Dyne Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Dyne Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dyne Therapeutics Notable Stakeholders
A Dyne Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dyne Therapeutics often face trade-offs trying to please all of them. Dyne Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dyne Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joshua Brumm | President CEO | Profile | |
| Kate Mitchell | VP Resources | Profile | |
| Romesh Subramanian | CoFounder Advisor | Profile | |
| Richard MBA | Senior Administration | Profile | |
| Ashish MBA | Chief Officer | Profile | |
| Oxana Beskrovnaya | Chief Officer | Profile | |
| Johanna FriedlNaderer | Chief Officer | Profile | |
| Lucia Celona | Chief Officer | Profile | |
| Daniel Wilson | Senior Legal | Profile | |
| MBA MD | Chief Officer | Profile | |
| Susanna MBA | Chief Officer | Profile | |
| MS MD | VP Pharmacovigilance | Profile | |
| Debra Feldman | Chief Officer | Profile | |
| John MBA | Chief Officer | Profile | |
| Gene Kim | VP Fin | Profile | |
| Amy Reilly | Senior Relations | Profile | |
| Jonathan MD | Chief Officer | Profile |
About Dyne Therapeutics Management Performance
The success or failure of an entity such as Dyne Therapeutics often depends on how effective the management is. Dyne Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Dyne management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Dyne management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. Dyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people.
Dyne Therapeutics Workforce Analysis
Traditionally, organizations such as Dyne Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dyne Therapeutics within its industry.Dyne Therapeutics Manpower Efficiency
Return on Dyne Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 18.7M | |
| Working Capital Per Employee | 3.2M | |
| Working Capital Per Executive | 36.3M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.